IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Notice published in newspapers regarding loss of Share Certificates04-05-2023
04-05-2023
IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - CEP Certificate For Paracetamol Issued By EDQM
In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that European Directorate for the Quality of Medicines & Health Care (EDQM) has issued a 'Certificate of Suitability for Paracetamol' on 3rd May 2023. This will enable the Company to export Paracetamol in European Market.04-05-2023
IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of lost share certificate03-05-2023
IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of lost share certificate01-05-2023
IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of newspaper publication of Audited Financial Results for the quarter and year ended 31st March 202329-04-2023
IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39 (3) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 201529-04-2023
Q4FY23 Quarterly & FY23 Annual Result Announced for IOL Chemicals and Pharmaceuticals Ltd.
IOL Chemicals and Pharmaceuticals announced Q4FY23 & FY23 result: Q4FY23: Total income for Q4FY23 stood at Rs 596 crore as against Rs 530 crore in Q3FY23 EBITDA for Q4FY23 at Rs 104 crore as compared to Rs 50 crore in Q3FY23 Net profit for Q4FY23 at Rs 65 crore as compared to Rs 24 crore in Q3FY23 FY23: Total income for FY23 stood at Rs 2,243 crore as compared to Rs 2,216 crore in FY22 EBITDA for FY23 at Rs 252 crore as compared to Rs 288 crore in FY22 Net profit for FY23 at Rs 140 crore as compared to Rs 166 crore in FY22 Commenting on the performance, Vikas Gupta, Joint Managing Director said, “The last quarter of the financial year has come out strong for us as we stabilized our operations in pharma and specialty chemicals segments with a focus on cost rationalisation and margin improvement. With significant operational, technical and commercial efficiencies, improved market combination and expecting sustainable demand as an alternative to China, we believe we are on a good upward trajectory." Result PDF28-04-2023
IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release - Financial Results for the quarter and year ended 31st March 202328-04-2023
IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Intimation Of Book Closure Pursuant To Regulation 42 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
We hereby inform that the 36th Annual General Meeting (AGM) of the Members of the Company is scheduled to be held on Thursday, 10th August 2023 through Video Conferencing/ Other Audio Visual Means ("VC/OAVM") Facility. Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Section 91 of the Companies Act, 2013, the Register of Members and Share Transfer Books of the Company will remain closed from 4th August 2023 to 10th August 2023 (both days inclusive) for the purpose of AGM of the Company.28-04-2023